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The attainment of therapeutic prescrib-
ing rights for New Zealand optometrists 
has been a gradual process. Numerous 
legislative changes have occurred over 
the past 30 years leading up to the gain-
ing of these rights.  
Early legislation
The original act that governed the practising 
of optometry in New Zealand contained a 
section that speciﬁcally prohibited the use 
of cycloplegic agents in measuring refrac-
tive status, or the use of any drug for the 
treatment of ocular diseases (Section 44, 
Optometrists and Dispensing Opticians 
Act 1976).1 The Medicines Act of 19812 
gave the government the ability to classify 
medicines and specify who could use them, 
the details of which appear monthly in the 
government newsletter the Gazette. The 
Medicines Regulations of 1984,3 through 
the 1981 Medicines Act, gave New Zea-
land optometrists the right to apply local 
anaesthetics ‘for the use in his practice as 
an optometrist’.
In 1996, an amendment to the 1976 
Optometrists and Dispensing Opticians Act 
gave optometrists the right to use cyclople-
gics for the purpose of refraction;4  however, 
it was not until 1998 that cyclopentolate was 
published in the Gazette for use by optom-
etrists. Prior to 1998, the use of cycloplegics 
by optometrists had to be under the direction 
of or a prescription from a medical profes-
sional (GP or ophthalmologist). 
Current legislation
Changes in legislation began with the New 
Zealand Government’s introduction of the 
Medicines Amendment Bill in 1998, and in 
2002 led to the New Prescribers Advisory 
Committee hearing applications for the ex-
tension of prescribing rights to new groups 
of health practitioners. 
The process of acquiring optometric 
prescribing rights was gradual. Submissions 
were made on behalf of optometrists by the 
Department of Optometry and Vision Sci-
ence at The University of Auckland and the 
New Zealand Association of Optometrists 
(NZAO). Unlike the attainment of nurse 
prescribing, for which a dedicated team of 
Ministry of Health staff had been working 
on the process, optometry had only the 
NZAO.
The initial submission to the New Prescrib-
ers Advisory Committee was rejected as the 
committee would accept only applications 
from health professional registration bodies 
and not from the professions themselves; 
however, the legislation that covered the 
Optometrists and Dispensing Opticians 
Board (ODOB) at that time did not pro-
vide avenues for promoting or furthering 
the profession. After much lobbying the 
NZAO and the Department of Optometry 
and Vision Science, with the support of the 
ODOB, were ﬁnally permitted to submit an 
application in May 2002.
The decision on the question of which 
classes of medicines optometrists could 
prescribe was made independently of the 
development of the guidelines for the use of 
the different classes of medicine. The appli-
cation was accepted and optometrists were 
included as registered health practitioners in 
the 2003 Health Practitioners Competence 
Assurance Act.5  The act was passed on 11 
September 2003 and came into full effect 
on 18 September 2004.  
Within the act, the ODOB is required to 
specify the Scope of Practice for optom-
etrists in New Zealand and the qualiﬁca-
tions required to attain these scopes. The 
scope deﬁnes what an optometrist can do, 
compared with the old act that deﬁned what 
optometrists could not do. Optometrists with 
therapeutic pharmaceutical agents (TPA) 
endorsement are allowed to prescribe thera-
peutic agents as detailed in the Gazette.
Undergraduate 
 therapeutic training
The New Zealand ODOB prescribes the 
qualiﬁcations necessary to register as a 
TPA endorsed optometrist. From 1999, the 
Optometry Council of Australia and New 
Zealand required that existing education 
programs in optometry begin the process 
of including training in therapeutic phar-
maceutical agents in their courses as a 
condition of maintaining their accredited 
status. The Department of Optometry and 
Vision Science at The University of Auckland 
began the process of changing its under-
graduate Bachelor of Optometry course to 
incorporate therapeutic training in 2000. 
The ﬁrst students eligible to be selected into 
the modiﬁed BOptom program began their 
university studies in 2002. Since 2006 all 
newly graduated optometrists have had TPA 
endorsement.
Postgraduate  therapeutic 
training
Postgraduate training in ocular therapeutics 
was initially provided by The Auckland 
Program in Ocular Therapeutics (TAPIOT). 
This program was designed in 2002-2003 
to meet the accreditation requirements 
of the Optometrists Registration Board of 
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 Victoria, the only board able to accredit any 
therapeutics courses in Australasia.  TAPIOT 
was modelled after the established course at 
The University of Melbourne. The ﬁrst cohort 
of optometrists completed this postgradu-
ate level program in 2004. In 2006 the 
program was restructured by dividing the 
content into three standard postgraduate 
courses. This enabled government funding 
to support the training.
On-going competence  in 
ocular  therapeutics
All TPA-endorsed optometrists are required 
to maintain competence through biannual 
requirements for continuing professional 
development hours, many of which are 
facilitated though seminars provided by 
local ophthalmologists.
Optometrist numbers
As of 31 March 2010, there were 685 
optometrists holding practising certiﬁcates 
from the ODOB, of whom 276 were TPA 
endorsed (40.29 per cent).6  This was an 
increase from 225 of 675 registered optom-
etrists (33.33 per cent) at 31 March 2009. 
Current medications
Since 1998, registered optometrists have 
been able to use diagnostic pharmaceutical 
agents within their practice (topical local 
anaesthetics, mydriatics and cycloplegics). 
Since 2004, TPA-endorsed optometrists 
have been able to prescribe a number of 
therapeutic agents.7 
Initially, optometrists were able to pre-
scribe 22 medications covering antiviral 
(acyclovir), antibacterial (chloramphenicol, 
ciproﬂoxacin, framycetin, fusidic acid, gen-
tamicin, gramicidin, neomycin, polymixin B, 
tobramycin and trimethoprim), anti-inﬂam-
matory (betamethasone, dexamethasone, 
diclofenac, ﬂuorometholone, ﬂubiprofen, 
ketorolac and prednisolone), anti-allergy 
(olopatadine at subsidised prescription 
rate), and cycloplegic (atropine, homatro-
pine, and hyoscine) modalities.
In August 2007, tropicamide and cyclo-
pentolate were added to the list of medicines 
able to be prescribed by TPA-endorsed op-
tometrists. In April 2009, chloramphenicol 
was reclassiﬁed by the government to a 
restricted medication, meaning that both 
pharmacists and registered optometrists 
could maintain stock and sell it to patients 
without having to write them a prescription.
Early prescribing
When optometrists first began prescrib-
ing, the New Zealand legislation did not 
cover the prescriptions under the HealthPac 
subsidy scheme available to other health 
practitioner prescribers. This meant that a 
pharmacist could not claim back part of the 
cost for subsidised medicines prescribed by 
an optometrist, and patients were forced to 
pay the full cost of the medication. The same 
prescription coming from an ophthalmolo-
gist was covered under the subsidy scheme. 
This duality was the result of the way in 
which the pharmaceutical budget was 
independently managed by PHARMAC, 
the Pharmaceutical Management Agency 
of New Zealand.
PHARMAC agreed to review the process 
of patient access to subsidies and changed 
its protocol to base access on patient and 
clinical attributes instead of being based on 
prescriber status as it had been. In March 
2006, the Ministry of Health changed the 
HealthPac payment and claiming system 
to allow pharmacists to claim the subsidies 
against scripts prescribed by optometrists 
and from 1 October, 2007 PHARMAC 
allowed access to subsidised eye prepara-
tions for all prescribers.
One of the conditions associated with the 
granting of prescribing rights to optometrists 
was that a record of all steroid prescriptions 
made was kept by each prescribing optom-
etrist.  These were collected by the Ministry 
of Health for monitoring purposes to ensure 
steroids were not being over-prescribed. This 
requirement was abolished in March 2006. 
The latest annual report from the ODOB6 
found that ‘optometrists are prescribing 
responsibly with no excessive use of antibiot-
ics or steroids’. 
The number of prescriptions written by 
TPA-endorsed optometrists has increased 
since the board ﬁrst began collecting re-
ports from the HealthPac reporting system 
in 2006. The majority of prescriptions in the 
quarter to 31 March 2010 were for antibac-
terial drugs (45 per cent), closely followed 
by anti-inﬂammatory drugs (19 per cent for 
steroids and 16 per cent for non-steroidal 
anti-inﬂammatory drugs).8
Future medications
The class of medicines that was absent from 
the initial list of allowed medicines was the 
anti-glaucoma preparations. The accredita-
tion requirements of both the graduate and 
undergraduate TPA courses means that 
optometrists trained in New Zealand have 
the knowledge, skills and observational 
experience in the use of these medications 
that satisﬁes boards in Australia. The profes-
sion is still keen to have this class added 
to the therapeutic scope of practice. The 
on-going discussions about the addition of 
the anti-glaucoma class of medicines to the 
TPA-endorsed scope of practice are again 
occurring independently of the discussions 
about the guidelines for the use of this class.
While still in its infancy, ocular therapeutic 
prescribing by optometrists in New Zealand 
has grown rapidly from the desire to provide 
the highest quality primary eye-care service 
possible to our patients.
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The profession has come a long way since winning the right to use topical anaesthetics in 1984
